Indication

Adult-onset Still's disease

Adult-onset Still's disease (AOSD) is a rare, systemic autoinflammatory disorder of unknown etiology that primarily affects young adults. Read more about Adult-onset Still's disease

3 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Adult-onset Still's disease therapies.

Showing 1–3 of 3 drugs

ILARIS (canakinumab/PF)

ANTI-INFLAMMATORY - INTERLEUKIN 1 RECEPTOR ANTAGONIST·ACUTE GOUTY ARTHRITIS·+7
Novartis Pharmaceuticals

ILARIS (canakinumab/PF)

ANTI-INFLAMMATORY - INTERLEUKIN 1 RECEPTOR ANTAGONIST·ACUTE GOUTY ARTHRITIS·+7
Novartis Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Adult-onset Still's disease preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Adult-onset Still's disease.

Adult-onset Still's disease (AOSD) is a rare, systemic autoinflammatory disorder of unknown etiology that primarily affects young adults.

Pathophysiologically, it is characterized by innate immune dysregulation marked by hyperactivation of macrophages and neutrophils alongside excessive production of proinflammatory cytokines, including interleukin-1 (IL-1), interleukin-6 (IL-6), and interleukin-18 (IL-18).

The condition classically manifests with a clinical triad of daily spiking quotidian fevers, an evanescent salmon-pink maculopapular rash, and inflammatory arthralgias or arthritis.

Additional hallmark systemic features include sore throat, lymphadenopathy, hepatosplenomegaly, serositis, and profound laboratory abnormalities such as marked leukocytosis and extreme hyperferritinemia.

Personalize your experience

Follow Adult-onset Still's disease and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it